NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

ACRX - Acelrx Pharmaceuticals Inc

AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Manage","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

# ACRXhart

Acelrx Pharmaceuticals Inc News


AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
MarketWatch (press release) - May 8, 2012
REDWOOD CITY, Calif., May 8, 2012 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) , ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute ...

AcelRx Pharmaceuticals Inc Announces Initiation Of Second Phase Three Clinical Trial For ARX-01
Reuters Key Development - Apr 12, 2012

AcelRx Pharmaceuticals Inc Receives Two Notices Of Allowance For Small-Volume Oral Transmucosal Dosage Forms
Reuters Key Development - Apr 11, 2012

AcelRx Pharmaceuticals Inc Announces Initiation Of Phase 3 Clinical Program For ARX-01, The Sufentanil NanoTab PCA System For The Treatment Of Post-Operative Pain
Reuters Key Development - Mar 7, 2012

AcelRx Pharmaceuticals Inc Secures $20 Million Loan Financing Agreement
Reuters Key Development - Jun 30, 2011

AcelRx Pharmaceuticals Inc Announces $5.6 Million Department of Defense Grant To Develop ARX-04
Reuters Key Development - Jun 16, 2011

AcelRx Pharmaceuticals Inc Raises $40 Million Through Initial Public Offering-Datamonitor's Financial Deals Tracker
Reuters Key Development - Feb 11, 2011

AcelRx Pharmaceuticals Inc Announces Positive Phase 2 Results From Study Of ARX-02 Sufentanil NanoTab Breakthrough Pain Management System In Treating Cancer Breakthrough Pain
Reuters Key Development - May 25, 2010

AcelRx Pharmaceuticals Inc Reports Positive Results From Clinical Trial Of Sublingual Sufentanil/Triazolam NanoTab Combination (ARX-03) In Treating Procedural Pain And Anxiety
Reuters Key Development - Jan 13, 2009

AcelRx Pharmaceuticals Inc Reports Positive Results From Phase 2 Clinical Trial Of Sublingual Sufentanil NanoTabs In Treating Post-Operative Pain
Reuters Key Development - Dec 9, 2008

NYSE Media Coverage Selection of the best articles found in your favorit medias

Next Company >>